JAMES CLEVELAND: Open Payments
NPI 1942895321 · CUMMING, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,022 in 61 payments from 18 companies in 2025. Trend: 2023 $752 · 2024 $1,347 · 2025 $1,022
Food & beverage: $1,022
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $264 |
| Novo Nordisk Inc | 6 | $105 |
| Axsome Therapeutics, Inc. | 3 | $72 |
| PFIZER INC. | 3 | $65 |
| Astellas Pharma US Inc | 3 | $58 |
| Inspire Medical Systems, Inc. | 2 | $58 |
| AstraZeneca Pharmaceuticals LP | 3 | $55 |
| Amgen Inc. | 3 | $47 |
| Esperion Therapeutics, Inc. | 2 | $43 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $42 |
Products named: VRAYLAR, UBRELVY, QULIPTA, Symbravo, Veozah, INSPIRE, AIRSUPRA, OTEZLA.
Industry payments across GA — which companies pay providers there.
